◀ Back to ERBB2
ERBB2 — ESR1
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
ERBB2
→
Complex of ERBB2-ESR1
(directlyIncreases, ERBB2/ESR1 Activity)
Stoica et al., Oncogene 2003*
Evidence: Taken together, our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation. This results in the activation of PI 3-K and Akt. Akt, in turn, may interact with nuclear ER-alpha, altering its expression and activity.
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Bai et al., Mol Endocrinol 2003
:
Finally, expression of the oncogenic activated
ErbB-2/Neu protein specifically
enhanced ERalpha but not ERbeta interactions with SRC RIDs to an extent similar to E2-stimulated interactions
Stoica et al., Oncogene 2003
:
Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on
ER-alpha expression and activity is also
mediated by
ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-alpha regulation
Stoica et al., Oncogene 2003
(Breast Neoplasms) :
Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on
ER-alpha expression and activity is
mediated by
ErbB2 and not by EGFR
Shyamala et al., Cancer Res 2006
(Breast Neoplasms) :
Effect of c-neu/
ErbB2 expression levels on
estrogen receptor alpha dependent proliferation in mammary epithelial cells : implications for breast cancer biology
Lehnes et al., Endocrinology 2007
(Cell Transformation, Neoplastic) :
Cumulatively, our results suggest that Akt1 and
ErbB2 are
involved in in vivo tumorigenesis and modulation of
estrogen receptor-alpha expression and activity